Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.56
CELG's Cash-to-Debt is ranked lower than
87% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CELG: 0.56 )
Ranked among companies with meaningful Cash-to-Debt only.
CELG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 9.31 Max: No Debt
Current: 0.56
Equity-to-Asset 0.24
CELG's Equity-to-Asset is ranked lower than
86% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CELG: 0.24 )
Ranked among companies with meaningful Equity-to-Asset only.
CELG' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.3  Med: 0.78 Max: 0.97
Current: 0.24
-0.3
0.97
Interest Coverage 6.33
CELG's Interest Coverage is ranked lower than
89% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 6.33 )
Ranked among companies with meaningful Interest Coverage only.
CELG' s Interest Coverage Range Over the Past 10 Years
Min: 6.33  Med: 27.63 Max: 428.04
Current: 6.33
6.33
428.04
Piotroski F-Score: 6
Altman Z-Score: 4.28
Beneish M-Score: -2.65
WACC vs ROIC
10.25%
19.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 28.20
CELG's Operating Margin % is ranked higher than
91% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CELG: 28.20 )
Ranked among companies with meaningful Operating Margin % only.
CELG' s Operating Margin % Range Over the Past 10 Years
Min: -64.94  Med: 29 Max: 32.84
Current: 28.2
-64.94
32.84
Net Margin % 17.80
CELG's Net Margin % is ranked higher than
87% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CELG: 17.80 )
Ranked among companies with meaningful Net Margin % only.
CELG' s Net Margin % Range Over the Past 10 Years
Min: -68.02  Med: 23.31 Max: 28.88
Current: 17.8
-68.02
28.88
ROE % 34.72
CELG's ROE % is ranked higher than
96% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CELG: 34.72 )
Ranked among companies with meaningful ROE % only.
CELG' s ROE % Range Over the Past 10 Years
Min: -48.42  Med: 24.32 Max: 34.72
Current: 34.72
-48.42
34.72
ROA % 7.44
CELG's ROA % is ranked higher than
88% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CELG: 7.44 )
Ranked among companies with meaningful ROA % only.
CELG' s ROA % Range Over the Past 10 Years
Min: -38.07  Med: 11.43 Max: 15.8
Current: 7.44
-38.07
15.8
ROC (Joel Greenblatt) % 183.43
CELG's ROC (Joel Greenblatt) % is ranked higher than
96% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CELG: 183.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CELG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -421.4  Med: 179.18 Max: 212.3
Current: 183.43
-421.4
212.3
3-Year Revenue Growth Rate 22.80
CELG's 3-Year Revenue Growth Rate is ranked higher than
73% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. CELG: 22.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CELG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -42.8  Med: 31 Max: 241.3
Current: 22.8
-42.8
241.3
3-Year EBITDA Growth Rate 19.30
CELG's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CELG: 19.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CELG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34  Med: 19.35 Max: 295.8
Current: 19.3
-34
295.8
3-Year EPS without NRI Growth Rate 14.00
CELG's 3-Year EPS without NRI Growth Rate is ranked higher than
68% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CELG: 14.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CELG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.8  Med: 14.7 Max: 109.7
Current: 14
-60.8
109.7
GuruFocus has detected 3 Warning Signs with Celgene Corp $CELG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CELG's 10-Y Financials

Financials (Next Earnings Date: 2017-04-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CELG Guru Trades in Q2 2016

Ronald Muhlenkamp 19,809 sh (New)
Ken Heebner 20,000 sh (New)
Jim Simons 563,038 sh (New)
Steven Cohen 21,200 sh (New)
Joel Greenblatt 317,274 sh (+360.37%)
Ray Dalio 7,300 sh (+78.05%)
Julian Robertson 379,140 sh (+65.68%)
RS Investment Management 141,861 sh (+27.75%)
Pioneer Investments 4,222,301 sh (+10.49%)
Ken Fisher 204,128 sh (+3.01%)
Murray Stahl 8,000 sh (unchged)
Lee Ainslie Sold Out
Mario Gabelli 26,988 sh (-0.57%)
Eaton Vance Worldwide Health Sciences Fund 139,500 sh (-45.51%)
» More
Q3 2016

CELG Guru Trades in Q3 2016

Paul Tudor Jones 2,500 sh (New)
Signature Select Canadian Fund 34,700 sh (New)
Steven Cohen 249,800 sh (+1078.30%)
Ray Dalio 35,700 sh (+389.04%)
Ronald Muhlenkamp 73,515 sh (+271.12%)
Jim Simons 1,225,638 sh (+117.68%)
Pioneer Investments 4,595,046 sh (+8.83%)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (+218.94%)
Ronald Muhlenkamp 3,000 sh (unchged)
Murray Stahl 8,000 sh (unchged)
Ken Heebner Sold Out
Ken Fisher 199,770 sh (-2.13%)
Julian Robertson 368,940 sh (-2.69%)
Joel Greenblatt 268,338 sh (-15.42%)
Mario Gabelli 15,888 sh (-41.13%)
» More
Q4 2016

CELG Guru Trades in Q4 2016

George Soros 3,500 sh (New)
Steven Cohen 646,900 sh (+158.97%)
Ken Fisher 203,488 sh (+1.86%)
Ronald Muhlenkamp 3,000 sh (unchged)
Murray Stahl 8,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (unchged)
Ray Dalio Sold Out
Ronald Muhlenkamp 72,688 sh (-1.12%)
Pioneer Investments 4,520,555 sh (-1.62%)
Paul Tudor Jones 2,100 sh (-16.00%)
Julian Robertson 298,740 sh (-19.03%)
Mario Gabelli 11,339 sh (-28.63%)
Jim Simons 751,338 sh (-38.70%)
Joel Greenblatt 119,987 sh (-55.29%)
» More
2017

CELG Guru Trades in 2017

Spiros Segalas 5,792,591 sh (-2.88%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:NONOF, NAS:GILD, NAS:TIG, NAS:AMGN, NAS:BIIB, OTCPK:SHPGF, OTCPK:CSLLY, NAS:REGN, OTCPK:ALIOY, NAS:ALXN, NAS:INCY, NAS:VRTX, OTCPK:GIKLY, NAS:BMRN, OTCPK:UCBJY, OTCPK:NVZMF, OTCPK:GMXAY, NAS:SGEN, NAS:ALKS, NAS:JAZZ » details
Traded in other countries:CLGN34.Brazil, CG3.Germany, CELG.Mexico, CELG.Switzerland, 0QYA.UK,
Headquarter Location:USA
Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014.

Top Ranked Articles about Celgene Corp

Gilead and Celgene Among Biotechnology Stocks to Buy Industry contains at least 2 stocks that gurus are adding to their portfolios
The general biotechnology industry offers gurus many opportunities to increase their portfolio returns. Several biotech stocks, including Gilead Sciences Inc. (NASDAQ:GILD) and Celgene Corp. (NASDAQ:CELG), have positive financial outlooks. Read more...

Ratios

vs
industry
vs
history
PE Ratio 49.43
CELG's PE Ratio is ranked lower than
72% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. CELG: 49.43 )
Ranked among companies with meaningful PE Ratio only.
CELG' s PE Ratio Range Over the Past 10 Years
Min: 17.92  Med: 46.14 Max: 603.25
Current: 49.43
17.92
603.25
Forward PE Ratio 17.04
CELG's Forward PE Ratio is ranked higher than
52% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. CELG: 17.04 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 49.43
CELG's PE Ratio without NRI is ranked lower than
72% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. CELG: 49.43 )
Ranked among companies with meaningful PE Ratio without NRI only.
CELG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.82  Med: 46.14 Max: 482.6
Current: 49.43
17.82
482.6
Price-to-Owner-Earnings 38.87
CELG's Price-to-Owner-Earnings is ranked lower than
54% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. CELG: 38.87 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CELG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.44  Med: 39.42 Max: 922
Current: 38.87
15.44
922
PB Ratio 14.48
CELG's PB Ratio is ranked lower than
91% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CELG: 14.48 )
Ranked among companies with meaningful PB Ratio only.
CELG' s PB Ratio Range Over the Past 10 Years
Min: 4.02  Med: 9.31 Max: 23.65
Current: 14.48
4.02
23.65
PS Ratio 8.83
CELG's PS Ratio is ranked higher than
58% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CELG: 8.83 )
Ranked among companies with meaningful PS Ratio only.
CELG' s PS Ratio Range Over the Past 10 Years
Min: 5.41  Med: 9.76 Max: 27.37
Current: 8.83
5.41
27.37
Price-to-Free-Cash-Flow 26.48
CELG's Price-to-Free-Cash-Flow is ranked lower than
52% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. CELG: 26.48 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CELG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.96  Med: 32.88 Max: 2438.33
Current: 26.48
14.96
2438.33
Price-to-Operating-Cash-Flow 24.86
CELG's Price-to-Operating-Cash-Flow is ranked lower than
57% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. CELG: 24.86 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CELG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.93  Med: 31.07 Max: 1279.09
Current: 24.86
13.93
1279.09
EV-to-EBIT 36.16
CELG's EV-to-EBIT is ranked lower than
71% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CELG: 36.16 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.6  Med: 33.9 Max: 144.7
Current: 36.16
-28.6
144.7
EV-to-EBITDA 30.30
CELG's EV-to-EBITDA is ranked lower than
67% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CELG: 30.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
CELG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.4  Med: 28.5 Max: 125.5
Current: 30.3
-31.4
125.5
PEG Ratio 3.05
CELG's PEG Ratio is ranked lower than
66% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. CELG: 3.05 )
Ranked among companies with meaningful PEG Ratio only.
CELG' s PEG Ratio Range Over the Past 10 Years
Min: 1.38  Med: 2.36 Max: 3.26
Current: 3.05
1.38
3.26
Shiller PE Ratio 100.91
CELG's Shiller PE Ratio is ranked lower than
70% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. CELG: 100.91 )
Ranked among companies with meaningful Shiller PE Ratio only.
CELG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 84.46  Med: 140.69 Max: 3211
Current: 100.91
84.46
3211
Current Ratio 3.67
CELG's Current Ratio is ranked lower than
54% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CELG: 3.67 )
Ranked among companies with meaningful Current Ratio only.
CELG' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 6.91 Max: 33.25
Current: 3.67
1.35
33.25
Quick Ratio 3.50
CELG's Quick Ratio is ranked lower than
53% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CELG: 3.50 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 6.82 Max: 33.25
Current: 3.5
1.13
33.25
Days Inventory 401.70
CELG's Days Inventory is ranked lower than
90% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. CELG: 401.70 )
Ranked among companies with meaningful Days Inventory only.
CELG' s Days Inventory Range Over the Past 10 Years
Min: 104.34  Med: 244.42 Max: 401.7
Current: 401.7
104.34
401.7
Days Sales Outstanding 52.68
CELG's Days Sales Outstanding is ranked higher than
57% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CELG: 52.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.42  Med: 57.78 Max: 71.27
Current: 52.68
43.42
71.27
Days Payable 205.92
CELG's Days Payable is ranked higher than
84% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. CELG: 205.92 )
Ranked among companies with meaningful Days Payable only.
CELG' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 139.99 Max: 209.22
Current: 205.92
61.81
209.22

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.80
CELG's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CELG: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CELG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.9  Med: -6.9 Max: 4.5
Current: 1.8
-23.9
4.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.44
CELG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
57% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. CELG: 2.44 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CELG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.8  Med: 5.47 Max: 55
Current: 2.44
1.8
55
Price-to-Median-PS-Value 0.90
CELG's Price-to-Median-PS-Value is ranked higher than
58% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CELG: 0.90 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CELG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.65  Med: 1.77 Max: 13.75
Current: 0.9
0.65
13.75
Price-to-Peter-Lynch-Fair-Value 2.99
CELG's Price-to-Peter-Lynch-Fair-Value is ranked lower than
71% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. CELG: 2.99 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CELG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.46  Med: 2 Max: 5.1
Current: 2.99
0.46
5.1
Earnings Yield (Greenblatt) % 2.77
CELG's Earnings Yield (Greenblatt) % is ranked higher than
77% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CELG: 2.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CELG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.7  Med: 2.8 Max: 6.7
Current: 2.77
0.7
6.7
Forward Rate of Return (Yacktman) % 18.93
CELG's Forward Rate of Return (Yacktman) % is ranked higher than
55% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. CELG: 18.93 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CELG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.1  Med: 2.2 Max: 34.8
Current: 18.93
0.1
34.8

More Statistics

Revenue (TTM) (Mil) $11,229
EPS (TTM) $ 2.49
Beta1.52
Short Percentage of Float1.16%
52-Week Range $94.42 - 127.64
Shares Outstanding (Mil)777.97

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 13,216 15,565 18,347
EPS ($) 7.14 8.79 10.95
EPS without NRI ($) 7.14 8.79 10.95
EPS Growth Rate
(Future 3Y To 5Y Estimate)
20.66%
Dividends per Share ($)
» More Articles for NAS:CELG

Headlines

Articles On GuruFocus.com
Study These Gurus, but Don’t Buy Their Funds Apr 14 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Feb 14 2017 
Celgene Switzerland Invests in Jounce Therapeutics Feb 02 2017 
Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary Jan 24 2017 
9 Stocks Ray Dalio Continues to Buy Dec 22 2016 
When Is the PEG Ratio Superior to the P/E Ratio? Part 2 Nov 03 2016 
Abbott Develops AML Tests With Celgene and Agios Oct 13 2016 
Celgene: Is It a Buy? Jun 21 2016 
5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
Gilead and Celgene Among Biotechnology Stocks to Buy May 26 2016 

More From Other Websites
Celgene research leader Dr. Rupert Vessey joins Juno board Apr 24 2017
Celgene (CELG) to Post Q1 Earnings: What's in the Cards? Apr 24 2017
Celgene Corp. – Value Analysis (NASDAQ:CELG) : April 24, 2017 Apr 24 2017
Better Buy: Gilead Sciences vs. Celgene Apr 24 2017
9 Reasons Celgene Could Be the World's Most Perfect Stock Apr 24 2017
Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector Apr 23 2017
3 Stocks That Growth Investors Should Love Apr 23 2017
3 Top Stocks to Buy With Your Tax Refund Apr 22 2017
Street Watches To See If $125,000 Drug Boosts Biogen's Results Apr 21 2017
Celgene Corp. breached its 50 day moving average in a Bullish Manner : CELG-US : April 21, 2017 Apr 21 2017
What to expect from biotech Apr 20 2017
​Celgene to expand in Cambridge, taking former Amgen space Apr 20 2017
Looking for a Smart Way to Use Your Tax Refund? Buy These 3 Stocks Apr 19 2017
Dow's Johnson & Johnson Highlights 'Multiple Issues' For Drugs, Biotechs Apr 18 2017
3 Cancer Drug Stocks That Could Make You Rich Apr 17 2017
Celgene Stock History: The Biotech's Path to Gigantic Gains Apr 14 2017
The Hot Stock: Alexion Pharmaceuticals Climbs 3.3% Apr 13 2017
3 Rock-Solid Stocks to Buy Before the Next Market Crash Apr 13 2017
Short Sellers Back Off Major Biotechs Apr 12 2017
Biotechs Catching Their Breath: Cramer's 'Off The Charts' Apr 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)